# Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial

> **NCT06178211** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Chest Hospital** · enrollment: 36 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Immunotherapy: Adebrelimab
- **DRUG:** chemotherapy: carboplatin plus nab-paclitaxel

## Key facts

- **NCT ID:** NCT06178211
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-12
- **Primary completion:** 2025-03
- **Final completion:** 2026-11
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2023-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06178211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06178211, "Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06178211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*